Pharmacokinetics, Safety and Tolerability of Single Sequential and Multiple Intravenous Infusions of Ulinastatin for Injection in Healthy Chinese Participants
A Placebo-Controlled, Double-Blind, Phase I Clinical Study to Evaluate Pharmacokinetic Characteristics, Safety and Tolerability of Single Sequential and Multiple Continuous Intravenous Infusions of Ulinastatin for Injection in Healthy Chinese Participants
This is a Phase 1 clinical study. The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of ulinastatin for injection after single sequential and multiple continuous intravenous infusions in healthy Chinese volunteers.
Key study questions:
- - How does ulinastatin behave in the body after single sequential and multiple continuous intravenous infusions?
- - What are the safety outcomes and side effects in healthy people receiving this investigational drug?
- Study participants will:
- - Complete screening assessments to check if they meet the study requirements.
- - Receive either ulinastatin for injection or placebo (inactive substance with no study drug) via intravenous drip.
- - Follow the study schedule for single sequential infusions and multiple continuous infusions.
- - Provide blood samples to measure drug concentration in the body.
- - Undergo safety evaluations including physical examinations, vital sign monitoring and laboratory tests throughout the study period.
- The study will compare data from participants receiving the study drug versus those receiving placebo to assess drug-related exposure and adverse reactions.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This is a single-center, randomized, double-blind, placebo-controlled Phase 1 study of ulinastatin for injection in healthy Chinese adults. Approximately 40 participants will be enrolled sequentially into 4 cohorts and randomized 8:2 to ulinastatin or placebo, to evaluate single ascending doses of 100,000 to 8,000,000 units and multiple ascending doses of 400,000 or 1,600,000 units administered three times daily for 4 consecutive days. Serial blood samples will be collected for non-compartmental pharmacokinetic analysis, and safety and tolerability will be assessed throughout the study.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 1
Contactos e Locais
Contato de estudo
- Nome: Mingjuan Hua
- Número de telefone: +86-20-38972288
- E-mail: huamj@techpool.com.cn
Locais de estudo
-
-
Anhui
-
Hefei, Anhui, China, 230601
- The Second Affiliated Hospital of Anhui Medical University
-
Contato:
- Wei Hu
- Número de telefone: 0551-63869420
- E-mail: hwgcp@ayefy.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
Participants must meet all of the following criteria to be enrolled:
- Healthy Chinese male or female participants, as confirmed by medical history, physical examination, vital signs, 12-lead ECG, chest X-ray, and laboratory tests at screening.
- Age 18 to 55 years, inclusive.
- Body mass index (BMI) 19.0 to 28.0 kg/m2, inclusive; body weight at least 45.0 kg for women and at least 50.0 kg for men.
- Able to understand the procedures and methods of the study, willing to comply strictly with the protocol, and able to provide written informed consent.
Exclusion Criteria:
-
Participants meeting any of the following criteria are not eligible for enrollment:
- Smoking more than 5 cigarettes per day within 3 months before screening, or unable to abstain from smoking from 48 hours before dosing through the study period.
- Alcohol intake exceeding 14 units per week within 3 months before screening (1 unit = 360 mL of beer, 45 mL of spirits containing 40% alcohol, or 150 mL of wine), or consumption of alcohol-containing products within 48 hours before the first dose, or unable to abstain from alcohol during the study, or a positive blood alcohol test at screening or at admission (Day -2).
- History of drug abuse within 6 months before screening.
- History or presence of severe cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease.
- History of malignancy of any organ system within 5 years before screening, whether treated or untreated, and regardless of evidence of local recurrence or metastasis.
- History of clinically significant electrocardiographic abnormalities.
- History of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, or neurologic disorders that may alter the absorption, metabolism, or elimination of drugs.
- Clinically significant abnormalities in laboratory tests at screening.
- History or evidence of renal impairment, manifested as clinically significant abnormalities in creatinine, blood urea nitrogen, or urea, or abnormal urine composition (e.g., proteinuria).
- Severe illness, severe infection, or trauma within 2 weeks before dosing.
- Blood donation of 400 mL or more within 3 months before dosing, or significant blood loss of at least 400 mL.
- Allergic constitution, history of drug or food allergy, or known hypersensitivity to the study drug or to components of similar drugs.
- Participation in any other clinical trial and receipt of an investigational drug or device within 3 months before dosing.
- Use of prescription drugs, over-the-counter drugs, herbal medicines, or food supplements (including vitamins), or any drug that may interfere with the interpretation of safety data, or any drug or herbal medicine with known common toxicity to major organs, within 2 weeks before dosing.
- Surgery within 3 months before the first dose, or planned surgery during the study period.
- Pregnant or lactating women, or men or women of reproductive potential who are unwilling to use effective contraception from the start of the study through 90 days after dosing.
- Positive test for hepatitis B surface antigen, hepatitis C virus antibody, human immunodeficiency virus (HIV) antibody, or Treponema pallidum antibody.
- Difficulty with intravenous administration or blood sampling, or history of needle phobia or hematophobia.
- Any other condition that, in the opinion of the investigator, may prevent the participant from completing the study or may place the participant at significant risk.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Ciência básica
- Alocação: Randomizado
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Cohort 1: Ulinastatin single ascending dose (100,000, 2,000,000, and 6,000,000 units)
Participants receive a single 2-hour intravenous infusion of ulinastatin 100,000 units on Day 1, 2,000,000 units on Day 4, and 6,000,000 units on Day 7. |
Name Ulinastatin for injection Type Drug Other Names Ulinastatin; UTI Lyophilized powder for injection, 100,000 units per vial; white to slightly yellow lyophilized cake or powder. Reconstituted and diluted in 250 mL of 5% glucose injection, then administered by intravenous infusion over 2 hours (±5 minutes). Single doses of 100,000 to 8,000,000 units were administered in the single-ascending-dose cohorts; doses of 400,000 or 1,600,000 units were administered three times daily for 4 consecutive days in the multiple-ascending-dose cohorts. Manufactured by Guangdong Techpool Biochemical Pharmaceutical Co., Ltd. |
|
Comparador de Placebo: Cohort 1: Placebo
Participants receive a single 2-hour intravenous infusion of placebo (5% glucose injection) on Days 1, 4, and 7, matching the ulinastatin schedule in Cohort 1. |
Name Placebo Type Drug Other Names 5% glucose injection 250 mL of 5% glucose injection, prepared and administered so as to be indistinguishable in appearance from the reconstituted study drug. Contains no active ingredient. |
|
Experimental: Cohort 2: Ulinastatin single ascending dose (1,000,000, 4,000,000, and 8,000,000 units)
Participants receive a single 2-hour intravenous infusion of ulinastatin 1,000,000 units on Day 1, 4,000,000 units on Day 4, and 8,000,000 units on Day 7. |
Name Ulinastatin for injection Type Drug Other Names Ulinastatin; UTI Lyophilized powder for injection, 100,000 units per vial; white to slightly yellow lyophilized cake or powder. Reconstituted and diluted in 250 mL of 5% glucose injection, then administered by intravenous infusion over 2 hours (±5 minutes). Single doses of 100,000 to 8,000,000 units were administered in the single-ascending-dose cohorts; doses of 400,000 or 1,600,000 units were administered three times daily for 4 consecutive days in the multiple-ascending-dose cohorts. Manufactured by Guangdong Techpool Biochemical Pharmaceutical Co., Ltd. |
|
Comparador de Placebo: Cohort 2: Placebo
Participants receive a single 2-hour intravenous infusion of placebo (5% glucose injection) on Days 1, 4, and 7, matching the ulinastatin schedule in Cohort 2. |
Name Placebo Type Drug Other Names 5% glucose injection 250 mL of 5% glucose injection, prepared and administered so as to be indistinguishable in appearance from the reconstituted study drug. Contains no active ingredient. |
|
Experimental: Cohort 3: Ulinastatin multiple ascending dose (400,000 units three times daily for 4 days)
Participants receive 2-hour intravenous infusions of ulinastatin 400,000 units three times daily (at 8:00, 16:00, and 23:00, ±1 hour) on Days 1 to 3, and one morning dose on Day 4 (last dose). |
Name Ulinastatin for injection Type Drug Other Names Ulinastatin; UTI Lyophilized powder for injection, 100,000 units per vial; white to slightly yellow lyophilized cake or powder. Reconstituted and diluted in 250 mL of 5% glucose injection, then administered by intravenous infusion over 2 hours (±5 minutes). Single doses of 100,000 to 8,000,000 units were administered in the single-ascending-dose cohorts; doses of 400,000 or 1,600,000 units were administered three times daily for 4 consecutive days in the multiple-ascending-dose cohorts. Manufactured by Guangdong Techpool Biochemical Pharmaceutical Co., Ltd. |
|
Comparador de Placebo: Cohort 3: Placebo
Participants receive infusions of placebo (5% glucose injection) three times daily on Days 1 to 3 and one morning dose on Day 4, matching the ulinastatin schedule in Cohort 3. |
Name Placebo Type Drug Other Names 5% glucose injection 250 mL of 5% glucose injection, prepared and administered so as to be indistinguishable in appearance from the reconstituted study drug. Contains no active ingredient. |
|
Experimental: Cohort 4: Ulinastatin multiple ascending dose (1,600,000 units three times daily for 4 days)
Participants receive 2-hour intravenous infusions of ulinastatin 1,600,000 units three times daily (at 8:00, 16:00, and 23:00, ±1 hour) on Days 1 to 3, and one morning dose on Day 4 (last dose). |
Name Ulinastatin for injection Type Drug Other Names Ulinastatin; UTI Lyophilized powder for injection, 100,000 units per vial; white to slightly yellow lyophilized cake or powder. Reconstituted and diluted in 250 mL of 5% glucose injection, then administered by intravenous infusion over 2 hours (±5 minutes). Single doses of 100,000 to 8,000,000 units were administered in the single-ascending-dose cohorts; doses of 400,000 or 1,600,000 units were administered three times daily for 4 consecutive days in the multiple-ascending-dose cohorts. Manufactured by Guangdong Techpool Biochemical Pharmaceutical Co., Ltd. |
|
Comparador de Placebo: Cohort 4: Placebo
Participants receive infusions of placebo (5% glucose injection) three times daily on Days 1 to 3 and one morning dose on Day 4, matching the ulinastatin schedule in Cohort 4. |
Name Placebo Type Drug Other Names 5% glucose injection 250 mL of 5% glucose injection, prepared and administered so as to be indistinguishable in appearance from the reconstituted study drug. Contains no active ingredient. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Peak plasma concentration(Cmax)
Prazo: Up to 24 hours after the start of each infusion on Days 1, 4, and 7
|
Descriptive statistics by dose level; non-compartmental analysis.Blood samples were also collected at matching time points on Day -1 (baseline) for endogenous baseline correction. |
Up to 24 hours after the start of each infusion on Days 1, 4, and 7
|
|
Area under the plasma concentration-time curve from time zero to the last quantifiable
Prazo: Up to 24 hours after the start of each infusion on Days 1, 4, and 7
|
Descriptive statistics by dose level; non-compartmental analysis.Blood samples were also collected at matching time points on Day -1 (baseline) for endogenous baseline correction. |
Up to 24 hours after the start of each infusion on Days 1, 4, and 7
|
|
Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf)
Prazo: Up to 24 hours after the start of each infusion on Days 1, 4, and 7
|
Descriptive statistics by dose level; non-compartmental analysis.Blood samples were also collected at matching time points on Day -1 (baseline) for endogenous baseline correction. |
Up to 24 hours after the start of each infusion on Days 1, 4, and 7
|
|
Time to reach peak plasma concentration (Tmax)
Prazo: Up to 24 hours after the start of each infusion on Days 1, 4, and 7
|
Descriptive statistics by dose level; non-compartmental analysis.Blood samples were also collected at matching time points on Day -1 (baseline) for endogenous baseline correction. |
Up to 24 hours after the start of each infusion on Days 1, 4, and 7
|
|
Terminal elimination half-life (t1/2)
Prazo: Up to 24 hours after the start of each infusion on Days 1, 4, and 7
|
Up to 24 hours after the start of each infusion on Days 1, 4, and 7
|
|
|
Apparent clearance (CL)
Prazo: Up to 24 hours after the start of each infusion on Days 1, 4, and 7
|
Up to 24 hours after the start of each infusion on Days 1, 4, and 7
|
|
|
Apparent volume of distribution (Vz)
Prazo: Up to 24 hours after the start of each infusion on Days 1, 4, and 7
|
Up to 24 hours after the start of each infusion on Days 1, 4, and 7
|
|
|
Peak plasma concentration at steady state (Cmax,ss)
Prazo: Up to 24 hours after the start of the Day 4 infusion (last dose)
|
Up to 24 hours after the start of the Day 4 infusion (last dose)
|
|
|
Trough plasma concentration at steady state (Cmin,ss)
Prazo: Predose on Day 4
|
Predose on Day 4
|
|
|
Time to reach peak plasma concentration at steady state (Tmax,ss)
Prazo: Up to 24 hours after the start of the Day 4 infusion (last dose)
|
Up to 24 hours after the start of the Day 4 infusion (last dose)
|
|
|
Area under the plasma concentration-time curve during a dosing interval at steady state (AUC0-tau,ss)
Prazo: Up to 24 hours after the start of the Day 4 infusion (last dose)
|
Up to 24 hours after the start of the Day 4 infusion (last dose)
|
|
|
Accumulation ratio based on Cmax and AUC0-tau (Rac)
Prazo: Up to 24 hours after the start of the Day 4 infusion (last dose)
|
Up to 24 hours after the start of the Day 4 infusion (last dose)
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
|---|---|
|
Incidence and severity of adverse events (AEs)
Prazo: From the first dose up to 7 days (±1 day) after the last dose
|
From the first dose up to 7 days (±1 day) after the last dose
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- HJG-WSTD-GDTP
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Individual participant data will not be shared. The data are proprietary to the sponsor and are not made available to external parties.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .